Antonio R Lucena-Araujo, Haesook T Kim, Carolina Thomé, Rafael H Jacomo, Raul A Melo, Rosane Bittencourt, Ricardo Pasquini, Katia Pagnano, Ana Beatriz F Glória, Maria de Lourdes Chauffaille, Melina Athayde, Carlos S Chiattone, Ingrid Mito, Rodrigo Bendlin, Carmino Souza, Cristina Bortolheiro, Juan L Coelho-Silva, Stanley L Schrier, Martin S Tallman, David Grimwade, Arnold Ganser, Nancy Berliner, Raul C Ribeiro, Francesco Lo-Coco, Bob Löwenberg, Miguel A Sanz, Eduardo M Rego
Journal: Blood 2016;126(20):2302-6
PMID: 26429976
The TP73 gene transcript is alternatively spliced and translated into the transcriptionally active (TAp73) or inactive (ΔNp73) isoforms, with opposite effects on the expression of p53 target genes and on apoptosis induction. The imbalance between ΔNp73 and TAp73 may contribute to tumorigenesis and resistance to chemotherapy in human cancers, including hematologic malignancies. In acute promyelocytic leukemia (APL), both isoforms are expressed, but their relevance in determining response to therapy and contribution to leukemogenesis remains unknown. Here, we provide the first evidence that a higher ΔNp73/TAp73 RNA expression ratio is associated with lower survival, lower disease-free survival, and higher risk of relapse in patients with APL homogeneously treated with all-trans retinoic acid and anthracycline-based chemotherapy, according to the International Consortium on Acute Promyelocytic Leukemia (IC-APL) study. Cox proportional hazards modeling showed that a high ΔNp73/TAp73 ratio was independently associated with shorter overall survival (hazard ratio, 4.47; 95% confidence interval, 1.64-12.2; P = .0035). Our data support the hypothesis that the ΔNp73/TAp73 ratio is an important determinant of clinical response in APL and may offer a therapeutic target for enhancing chemosensitivity in blast cells.
© 2015 by The American Society of Hematology.
Full Text Sources:
Other Literature Sources:
Miscellaneous:
Research Materials:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.